WCN26-5001 ACYLCARNITINES IN PLASMA AND URINE ASSOCIATED WITH REMISSION OF PROTEINURIA IN FSGS/MCD: UNTARGETED METABOLOMIC ANALYSES FROM THE NEPTUNE COHORT

Read full text Summarise with VIRAT
Authors: Takaya Ozeki, Fadhl Alakwaa, Anna Vachaparampil Mathew, Yelena R. Drexler, Matthias Kretzler, Laura Mariani
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Remission of proteinuria in focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is closely linked to disease progression. However, the metabolic mechanisms underlying FSGS/MCD remain largely unknown, and predicting treatment response remains challenging. Acylcarnitines (ACs) are key intermediates in energy metabolism, facilitating the transport of fatty acids into mitochondria for β-oxidation. In kidney diseases, mitochondrial dysfunction and impaired fatty acid oxidation contribute to disease pathophysiology and are associated with dysregulated acylcarnitine profiles.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Metabolomics and Mass Spectrometry Studies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104473–104473
Publication date
25 March 2026
Language
EN